Brexpiprazole augmentation of aripiprazole once-monthly in schizophrenia spectrum disorders: A 12-week, open-label, randomised controlled pilot trial (BREATH-JS study)
Therapeutic Advances in Psychopharmacology · 2026-11 · 16
DOI: 10.1177/20451253261507451 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Psychopharmacology, online erschienen am 13.11.2026. Verfasst von Yoshiteru Takekita und 15 weiteren Autor:innen. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Aripiprazole once-monthly (AOM) cannot be escalated beyond 400 mg because of its formulation, and evidence on how to manage residual symptoms in patients maintained on AOM is scarce.
Objectives
To examine the efficacy and tolerability of brexpiprazole augmentation in patients with schizophrenia spectrum disorders receiving AOM maintenance treatment.
Design
A 12-week, multicentre, open-label, parallel-group, randomised controlled pilot trial.
Methods
Thirty outpatients with schizophrenia or schizoaffective disorder who had been receiving AOM for at least 2 months (all on 400 mg every 4 weeks) and had a Positive and Negative Syndrome Scale (PANSS) total score of 120 or less were randomly assigned in a 1:1 ratio to brexpiprazole augmentation or AOM continuation, with concealed allocation; 29 (brexpiprazole augmentation, 14; AOM continuation, 15) were analysed. The primary outcome was the change in the PANSS total score to week 12, analysed with a mixed-effects model for repeated measures.
Results
The adjusted between-group difference in the PANSS total score at week 12 was −12.4 (95% CI, −21.2 to −3.5; P = 0.008), favouring brexpiprazole augmentation, and this difference was apparent from week 4. Greater improvement was seen across all Marder five factors. A reduction of 20% or more occurred only in the brexpiprazole augmentation group (6/14, 42.9%; AOM continuation, 0/15; P = 0.006). Adverse events did not differ between groups; no worsening in body weight, metabolic parameters, or prolactin was observed, and akathisia decreased in the brexpiprazole augmentation group ( P = 0.011).
Conclusion
Brexpiprazole augmentation of AOM maintenance treatment improved the PANSS total score and was well tolerated. As this was an open-label, exploratory pilot trial, the findings are hypothesis-generating and require verification in larger, blinded, randomised controlled trials.
Zitieren
APA
Takekita, Y., Takano, C., Koshikawa, Y., Funatsuki, T., Takahashi, A., Murase, Y., Bando, H., Minami, S., Shimamoto, Y., Shimizu, T., Kojima, Y., Tanaka, Y., Sunada, N., Ogata, H., Aoki, N., & Kato, M. (2026). Brexpiprazole augmentation of aripiprazole once-monthly in schizophrenia spectrum disorders: A 12-week, open-label, randomised controlled pilot trial (BREATH-JS study). Therapeutic Advances in Psychopharmacology, 16. https://doi.org/10.1177/20451253261507451
Vancouver
Takekita Y, Takano C, Koshikawa Y, Funatsuki T, Takahashi A, Murase Y, et al. Brexpiprazole augmentation of aripiprazole once-monthly in schizophrenia spectrum disorders: A 12-week, open-label, randomised controlled pilot trial (BREATH-JS study). Therapeutic Advances in Psychopharmacology. 2026;16. doi:10.1177/20451253261507451
BibTeX
@article{Takekita2026,
author = {Takekita, Yoshiteru and Takano, Chikashi and Koshikawa, Yosuke and Funatsuki, Toshiya and Takahashi, Ai and Murase, Yuji and Bando, Hiroki and Minami, Shota and Shimamoto, Yutaro and Shimizu, Toshiyuki and Kojima, Yuki and Tanaka, Yuki and Sunada, Naotaka and Ogata, Haruhiko and Aoki, Nobuatsu and Kato, Masaki},
title = {Brexpiprazole augmentation of aripiprazole once-monthly in schizophrenia spectrum disorders: A 12-week, open-label, randomised controlled pilot trial (BREATH-JS study)},
journal = {Therapeutic Advances in Psychopharmacology},
year = {2026},
volume = {16},
doi = {10.1177/20451253261507451}
}
EUVIMED